Eli Lilly slides as weekly GLP-1 prescription data raises near-term demand questions

Eli Lilly and Company (LLY) is down 4.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The drop appears tied to investor jitters around near-term demand signals for Lilly’s GLP-1 franchise, particularly as the newly launched oral obesity pill Foundayo begins its commercial ramp. With the stock priced for strong execution, even “mixed” weekly prescription trends can pressure shares ahead of the next earnings update.

Details:

Weekly U.S. prescription tracking for key GLP-1 products showed steady growth in diabetes scripts but a read-through that wasn’t strong enough to offset concerns about obesity share and the early Foundayo ramp.

Lilly’s Foundayo (orforglipron) became available in the U.S. after FDA approval on April 1, 2026, putting heightened attention on early patient starts and access dynamics.

Foundayo’s rollout has included direct-to-patient distribution and discounting/affordability programs, which can support uptake but also keeps investors focused on net pricing and mix.

Lilly is scheduled to report first-quarter 2026 results on April 30, 2026, which can amplify sensitivity to any near-term datapoints on GLP-1 momentum.

Sources:

Eli Lilly Investor Relations, Investing.com, Associated Press

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LLY Insider Trading Activity

$LLY insiders have traded $LLY stock on the open market 200 times in the past 6 months. Of those trades, 0 have been purchases and 200 have been sales.

Here’s a breakdown of recent trading of $LLY stock by insiders over the last 6 months:

ENDOWMENT INC LILLY has made 0 purchases and 199 sales selling 2,320,066 shares for an estimated $2,287,207,433.
DONALD A ZAKROWSKI (SVP, Finance, & CAO) sold 1,000 shares for an estimated $1,010,500

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EARLY ACCESS

Receive LLY Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$LLY Hedge Fund Activity

We have seen 2,040 institutional investors add shares of $LLY stock to their portfolio, and 1,814 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 19,232,498 shares (-74.7%) from their portfolio in Q4 2025, for an estimated $20,668,780,950
J. STERN & CO. LLP added 4,038,502 shares (+46191.3%) to their portfolio in Q4 2025, for an estimated $4,340,097,329
JPMORGAN CHASE & CO added 2,729,791 shares (+26.6%) to their portfolio in Q4 2025, for an estimated $2,933,651,791
CARDANO RISK MANAGEMENT B.V. removed 2,124,209 shares (-89.4%) from their portfolio in Q1 2026, for an estimated $1,940,273,742
FMR LLC added 1,549,858 shares (+6.4%) to their portfolio in Q4 2025, for an estimated $1,665,601,395
PRIMECAP MANAGEMENT CO/CA/ removed 1,529,556 shares (-14.2%) from their portfolio in Q4 2025, for an estimated $1,643,783,242
PRICE T ROWE ASSOCIATES INC /MD/ added 1,432,069 shares (+10.6%) to their portfolio in Q4 2025, for an estimated $1,539,015,912

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$LLY Congressional Stock Trading

Members of Congress have traded $LLY stock 13 times in the past 6 months. Of those trades, 5 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $LLY stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 11/18 and 1 sale worth up to $15,000 on 03/13.
REPRESENTATIVE DAVID TAYLOR has traded it 4 times. They made 1 purchase worth up to $15,000 on 02/26 and 3 sales worth up to $45,000 on 02/09, 01/16, 12/10.
SENATOR ANGUS S. KING JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 12/29 and 1 sale worth up to $15,000 on 02/13.
SENATOR MARKWAYNE MULLIN purchased up to $50,000 on 12/29.
REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/18, 11/13.
SENATOR JOHN BOOZMAN sold up to $15,000 on 11/21.
SENATOR SHELLEY MOORE CAPITO purchased up to $15,000 on 10/24.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$LLY Analyst Ratings

Wall Street analysts have issued reports on $LLY in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 01/20/2026
B of A Securities issued a "Buy" rating on 12/15/2025
Wells Fargo issued a "Overweight" rating on 12/10/2025
BMO Capital issued a "Outperform" rating on 12/04/2025
Morgan Stanley issued a "Overweight" rating on 11/24/2025
Bernstein issued a "Outperform" rating on 11/24/2025
Truist Securities issued a "Buy" rating on 11/19/2025

To track analyst ratings and price targets for $LLY, check out Quiver Quantitative's $LLY forecast page.

$LLY Price Targets

Multiple analysts have issued price targets for $LLY recently. We have seen 19 analysts offer price targets for $LLY in the last 6 months, with a median target of $1250.0.

Here are some recent targets:

Seamus Fernandez from Guggenheim set a target price of $1183.0 on 04/22/2026
Terence Flynn from Morgan Stanley set a target price of $1327.0 on 04/10/2026
Jason Gerberry from B of A Securities set a target price of $1294.0 on 04/02/2026
Rajesh Kumar from HSBC set a target price of $850.0 on 03/17/2026
Trung Huynh from RBC Capital set a target price of $1250.0 on 02/25/2026
Emily Field from Barclays set a target price of $1350.0 on 02/20/2026
James Shin from Deutsche Bank set a target price of $1285.0 on 02/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.